Influence of the spacer on the inhibitory effect of different polycarbophil-protease inhibitor conjugates

被引:8
作者
Marschütz, MK
Veronese, FM
Bernkop-Schnürch, A
机构
[1] Univ Vienna, Inst Pharmaceut Technol & Biopharmaceut, Ctr Pharm, A-1090 Vienna, Austria
[2] Univ Padua, Dept Pharmaceut Sci, Padua, Italy
关键词
antipain; chymostatin; elastatinal; mucoadhesive drug-carrier matrix; oral peptide drug delivery; poly(ethylene glycol); polycarbophil; protease inhibitor;
D O I
10.1016/S0939-6411(01)00175-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Within the present study various polycarbophil (PCP)-serine protease inhibitor conjugates were synthesized and the influence of different spacers on their inhibitory efficacy was evaluated in vitro. Results demonstrated that 4.2 +/- 0.15 units (n = 3; +/- SD) of alpha -chymotrypsin were inhibited by 50% utilizing 0.86% (w/v) of a PCP-tetramethylenediamine (TMDA)-chymostatin 20:1 conjugate. In contrast, only 0.6 +/- 0.05 units (n = 3; +/- SD) of alpha -chymotrypsin were inhibited by a corresponding PCP-poly(ethylene glycol) (PEG)-chymostatin conjugate. Inhibitory effects of PCP-TMDA-antipain and -elastatinal conjugates towards trypsin and elastase, respectively, were also significantly higher (P < 0.05) than those of corresponding PCP-PEG-inhibitor conjugates. Hence, the great impact of the molecular size as well as the structure of the spacer on resulting polymer-inhibitor conjugates could be demonstrated. The small and rigid C4-spacer TMDA (molecular weight (MW) 161.1) was thereby shown to be highly advantageous over a long, hydrophilic and flexible PEG-diamine spacer (MW 3400). Results obtained should provide helpful basic knowledge for the development of mucoadhesive poly mer-inhibitor conjugates used as auxiliary agents for the oral administration of peptide drugs. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 17 条
[1]  
Bemkop-Schnurch A., 1998, J CONTROL RELEASE, V52, P1
[2]   Synthesis, development and in vitro evaluation of drug delivery systems with protective effect against degradation by pepsin [J].
Bernkop-Schnürch, A ;
Kirchmayer, R ;
Kratzel, M .
JOURNAL OF DRUG TARGETING, 1999, 7 (01) :55-63
[3]   Synthesis and in vitro evaluation of chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral delivery of peptides and proteins [J].
Bernkop-Schnürch, A ;
Scerbe-Saiko, A .
PHARMACEUTICAL RESEARCH, 1998, 15 (02) :263-269
[4]   Synthesis and evaluation of a modified mucoadhesive polymer protecting from alpha-chymotrypsinic degradation [J].
BernkopSchnurch, A ;
Apprich, I .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 146 (02) :247-254
[5]   Modified mucoadhesive polymers for the peroral administration of mainly elastase degradable therapeutic (poly)peptides [J].
BernkopSchnurch, A ;
Schwarz, GH ;
Kratzel, M .
JOURNAL OF CONTROLLED RELEASE, 1997, 47 (02) :113-121
[6]   MUCOADHESION OF POLY(2-HYDROXYETHYL METHACRYLATE) IS IMPROVED WHEN LINEAR POLY(ETHYLENE OXIDE) CHAINS ARE ADDED TO THE POLYMER NETWORK [J].
DEASCENTIIS, A ;
DEGRAZIA, JL ;
BOWMAN, CN ;
COLOMBO, P ;
PEPPAS, NA .
JOURNAL OF CONTROLLED RELEASE, 1995, 33 (01) :197-201
[7]   PROMOTING EFFECT OF THE NEW CHYMOTRYPSIN INHIBITOR FK-448 ON THE INTESTINAL-ABSORPTION OF INSULIN IN RATS AND DOGS [J].
FUJII, S ;
YOKOYAMA, T ;
IKEGAYA, K ;
SATO, F ;
YOKOO, N .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (08) :545-549
[8]   ORAL ABSORPTION OF PEPTIDES - THE EFFECT OF ABSORPTION SITE AND ENZYME-INHIBITION ON THE SYSTEMIC AVAILABILITY OF METKEPHAMID [J].
LANGGUTH, P ;
MERKLE, HP ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1994, 11 (04) :528-535
[9]  
LEHR CM, 1994, CRIT REV THER DRUG, V11, P119
[10]   Oral peptide drug delivery:: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro [J].
Marschütz, MK ;
Bernkop-Schnürch, A .
BIOMATERIALS, 2000, 21 (14) :1499-1507